Shots:

• The companies collaborated to evaluate Imugene’s PD1-Vaxx (B-cell activating immunotherapy) + atezolizumab (immune checkpoint inhibitor targeting PD-L1) in P-Ib trial in patients with NSCLC at sites in USA & Australia
• The objectives of the P-1b dose escalation/expansion trial is to determine safety, efficacy & optimal dose of PD1-Vaxx + atezolizumab as 1L therapy in ICI treatment naïve NSCLC patients or ICI pretreated patients
• Imugene will be the sponsor of study & will fund the clinical study while Roche will supply atezolizumab. Additionally, the therapy also has approved in four indications in advanced NSCLC as monothx. or in combination with targeted therapies & CT

Ref: Imugene | Image: Roche